Is ADMA Biologics Stock a Good Investment?
ADMA Biologics Investment Advice | ADMA |
- Examine ADMA Biologics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research ADMA Biologics' leadership team and their track record. Good management can help ADMA Biologics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact ADMA Biologics' business and its evolving consumer preferences.
- Compare ADMA Biologics' performance and market position to its competitors. Analyze how ADMA Biologics is positioned in terms of product offerings, innovation, and market share.
- Check if ADMA Biologics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about ADMA Biologics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in ADMA Biologics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if ADMA Biologics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves slightly opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine ADMA Biologics Stock
Researching ADMA Biologics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 88.0% of the company shares are held by institutions such as insurance companies. The company had not issued any dividends in recent years.
To determine if ADMA Biologics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding ADMA Biologics' research are outlined below:
| ADMA Biologics had very high historical volatility over the last 90 days | |
| Over 88.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Why Adma Biologics Outpaced the Stock Market Today |
ADMA Biologics Quarterly Accounts Payable |
|
ADMA Biologics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in ADMA Biologics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ADMA Biologics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact ADMA Biologics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises ADMA Biologics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-08-09 | 2023-06-30 | -0.02 | -0.03 | -0.01 | 50 | ||
2023-05-10 | 2023-03-31 | -0.04 | -0.03 | 0.01 | 25 | ||
2022-08-10 | 2022-06-30 | -0.08 | -0.07 | 0.01 | 12 | ||
2024-11-07 | 2024-09-30 | 0.13 | 0.15 | 0.02 | 15 | ||
2024-05-09 | 2024-03-31 | 0.06 | 0.08 | 0.02 | 33 | ||
2023-11-08 | 2023-09-30 | -0.01 | 0.01 | 0.02 | 200 | ||
2022-05-11 | 2022-03-31 | -0.08 | -0.1 | -0.02 | 25 | ||
2021-03-25 | 2020-12-31 | -0.16 | -0.2 | -0.04 | 25 |
Know ADMA Biologics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ADMA Biologics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ADMA Biologics backward and forwards among themselves. ADMA Biologics' institutional investor refers to the entity that pools money to purchase ADMA Biologics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Perpetual Ltd | 2024-12-31 | 3.6 M | Oberweis Asset Management Inc | 2024-12-31 | 3.3 M | Fmr Inc | 2024-12-31 | 3.2 M | D. E. Shaw & Co Lp | 2024-12-31 | 3.1 M | Two Sigma Advisers, Llc | 2024-12-31 | 3 M | Allspring Global Investments Holdings, Llc | 2024-12-31 | 2.8 M | Arrowstreet Capital Limited Partnership | 2024-12-31 | 2.8 M | Goldman Sachs Group Inc | 2024-12-31 | 2.7 M | Northern Trust Corp | 2024-12-31 | 2.6 M | Blackrock Inc | 2024-12-31 | 38.1 M | Vanguard Group Inc | 2024-12-31 | 18.2 M |
ADMA Biologics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.7 B.Market Cap |
|
ADMA Biologics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.41 | 0.43 | |
| Return On Capital Employed | 0.32 | 0.30 | |
| Return On Assets | 0.40 | 0.42 | |
| Return On Equity | 0.57 | 0.54 |
Determining ADMA Biologics' profitability involves analyzing its financial statements and using various financial metrics to determine if ADMA Biologics is a good buy. For example, gross profit margin measures ADMA Biologics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of ADMA Biologics' profitability and make more informed investment decisions.
ADMA Biologics' Earnings Breakdown by Geography
Please note, the presentation of ADMA Biologics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ADMA Biologics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of ADMA Biologics' management manipulating its earnings.
Evaluate ADMA Biologics' management efficiency
ADMA Biologics has return on total asset (ROA) of 0.2124 % which means that it generated a profit of $0.2124 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.8164 %, meaning that it created $0.8164 on every $100 dollars invested by stockholders. ADMA Biologics' management efficiency ratios could be used to measure how well ADMA Biologics manages its routine affairs as well as how well it operates its assets and liabilities. At present, ADMA Biologics' Return On Tangible Assets are projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.42, whereas Return On Capital Employed is forecasted to decline to 0.30. At present, ADMA Biologics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 348 M, whereas Other Assets are forecasted to decline to 1.09.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.50 | 1.57 | |
| Tangible Book Value Per Share | 1.48 | 1.55 | |
| Enterprise Value Over EBITDA | 28.61 | 30.04 | |
| Price Book Value Ratio | 11.45 | 12.03 | |
| Enterprise Value Multiple | 28.61 | 30.04 | |
| Price Fair Value | 11.45 | 12.03 | |
| Enterprise Value | 4 B | 4.2 B |
ADMA Biologics has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Beta 0.604 |
Basic technical analysis of ADMA Stock
As of the 22nd of March, ADMA Biologics shows the Semi Deviation of 3.13, mean deviation of 2.39, and Risk Adjusted Performance of 0.0416. ADMA Biologics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.ADMA Biologics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ADMA Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on ADMA Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ADMA Biologics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ADMA Biologics' Outstanding Corporate Bonds
ADMA Biologics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ADMA Biologics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ADMA bonds can be classified according to their maturity, which is the date when ADMA Biologics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| ABNANV 3324 13 MAR 37 Corp BondUS00084DAV29 | View | |
| ABNANV 1542 16 JUN 27 Corp BondUS00084DAU46 | View | |
| ABNANV 247 13 DEC 29 Corp BondUS00084DAW02 | View | |
| ABNANV 48 18 APR 26 Corp BondUS00084DAL47 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand ADMA Biologics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing ADMA Biologics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0416 | |||
| Market Risk Adjusted Performance | (0.15) | |||
| Mean Deviation | 2.39 | |||
| Semi Deviation | 3.13 | |||
| Downside Deviation | 3.3 | |||
| Coefficient Of Variation | 2588.15 | |||
| Standard Deviation | 3.3 | |||
| Variance | 10.9 | |||
| Information Ratio | 0.0575 | |||
| Jensen Alpha | 0.065 | |||
| Total Risk Alpha | 0.3868 | |||
| Sortino Ratio | 0.0575 | |||
| Treynor Ratio | (0.16) | |||
| Maximum Drawdown | 15.93 | |||
| Value At Risk | (4.68) | |||
| Potential Upside | 6.15 | |||
| Downside Variance | 10.89 | |||
| Semi Variance | 9.77 | |||
| Expected Short fall | (2.52) | |||
| Skewness | 0.0139 | |||
| Kurtosis | 2.16 |
| Risk Adjusted Performance | 0.0416 | |||
| Market Risk Adjusted Performance | (0.15) | |||
| Mean Deviation | 2.39 | |||
| Semi Deviation | 3.13 | |||
| Downside Deviation | 3.3 | |||
| Coefficient Of Variation | 2588.15 | |||
| Standard Deviation | 3.3 | |||
| Variance | 10.9 | |||
| Information Ratio | 0.0575 | |||
| Jensen Alpha | 0.065 | |||
| Total Risk Alpha | 0.3868 | |||
| Sortino Ratio | 0.0575 | |||
| Treynor Ratio | (0.16) | |||
| Maximum Drawdown | 15.93 | |||
| Value At Risk | (4.68) | |||
| Potential Upside | 6.15 | |||
| Downside Variance | 10.89 | |||
| Semi Variance | 9.77 | |||
| Expected Short fall | (2.52) | |||
| Skewness | 0.0139 | |||
| Kurtosis | 2.16 |
Consider ADMA Biologics' intraday indicators
ADMA Biologics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ADMA Biologics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
ADMA Biologics Corporate Filings
F4 | 21st of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 18th of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 3rd of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 7th of February 2025 Other Reports | ViewVerify |
ADMA Stock media impact
Far too much social signal, news, headlines, and media speculation about ADMA Biologics that are available to investors today. That information is available publicly through ADMA media outlets and privately through word of mouth or via ADMA internal channels. However, regardless of the origin, that massive amount of ADMA data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of ADMA Biologics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ADMA Biologics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ADMA Biologics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ADMA Biologics alpha.
ADMA Biologics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards ADMA Biologics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
ADMA Biologics Maximum Pain Price Across May 16th 2025 Option Contracts
ADMA Biologics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of ADMA Biologics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of ADMA Biologics' options.
ADMA Biologics Corporate Management
| CPA CPA | CFO VP | Profile | |
| Michael Goldstein | Sr Counsel | Profile | |
| Neal Fitzpatrick | Vice Sales | Profile | |
| Kaitlin Kestenberg | Project Compliance | Profile | |
| Cyndi Tolman | VP Services | Profile | |
| Dr DPS | CoFounder Chairman | Profile |
Already Invested in ADMA Biologics?
The danger of trading ADMA Biologics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ADMA Biologics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ADMA Biologics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ADMA Biologics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether ADMA Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ADMA Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Adma Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Adma Biologics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 14 | Earnings Share 0.81 | Revenue Per Share | Quarterly Revenue Growth 0.591 | Return On Assets |
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between ADMA Biologics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if ADMA Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.